Thursday September 20, 2012 0 comments
BOULDER - FierceBiotech has named miRagen Therapeutics one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.
"Over the past year, mirage made a big impression on the biopharma community with its major partnership with Servier and the recent publication in Cell that exposes new insights about the heart's role in metabolism and how the company's lead drug could provide both cardiovascular and metabolic benefits," said Ryan McBride, FierceBiotech executive editor.
"Add a $20 million venture round in the spring and you'll see why its work on cardiovascular and muscle disease has grabbed our attention."
The Fierce 15 celebrates the spirit of being "fierce," - championing innovation and creativity even in the face of intense competition.
"miRagen is dedicated to improving patients' lives through the discovery and development of innovative microRNA-based therapeutics," said William S. Marshall, company president and CEO.
"Recognition as a Fierce 15 company is a true honor and reflects our commitment to harness the power of microRNA biology to treat diseases where targeted pathway intervention may offer a hope for treatments that have previously been elusive."
A complete list of the Fierce 15 is available at www.fiercebiotech.com.